Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAMIGA: Continuous Bevacizumab in Glioblastoma
NCT01860638Phase 2Completed
- Sponsor
- Roche
- Start
- Aug 2013
- Primary completion
- Jan 2017
- Modality
- Monoclonal Antibodies
- Countries
- 15
01
Overview
A Phase 2 trial of bevacizumab in glioblastoma (GBM), sponsored by Roche. Started Aug 2013; status: completed.
02
Drugs
bevacizumab
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT01860638.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01860638.